Healthcare AI is moving faster than many health systems can govern it. My take: this webinar series is useful because it shows teams how to track AI tools, review vendor risk, report issues to the board, and watch for threats like hallucinations, drift, and prompt injection before they become patient safety, privacy, or security problems.
If I had to sum up the article in a few lines, it comes down to this:
- AI governance must start before deployment, not after.
- Boards need direct visibility into safety, cyber, vendor, and compliance risk.
- Vendor review for AI is different from normal software review because it includes training data, model changes, fourth-party exposure, and PHI use.
- Security teams need AI-specific controls for agent misuse, model theft, drift, and shadow AI.
- Cross-functional ownership matters because security, legal, clinical, IT, privacy, and procurement all hold part of the risk.
A few facts stand out. The piece points to a 7-phase third-party AI risk lifecycle and highlights ANSI/HSI 2800:2025 as a U.S. standard for AI governance in healthcare. That matters because many organizations still lack a clear AI inventory, a set approval path, and named owners for monitoring.
Quick Comparison
| Area | What the article says teams should do |
|---|---|
| Governance | Build a cross-functional AI committee and tie AI into enterprise risk work |
| Board oversight | Report on patient safety, cyber events, vendor exposure, compliance status, and open gaps |
| Vendor review | Check contracts, PHI retraining terms, model updates, data lineage, and fourth-party dependencies |
| Security | Watch for prompt injection, hallucinations, drift, model theft, agent misuse, and shadow AI |
| Day-to-day use | Map each AI use case to risks, owners, controls, and review steps |
What I like here is that the article stays focused on execution. It is not about AI hype. It is about who owns the risk, what teams should review, and how health systems can put guardrails around AI use in clinical and business settings.
From Deployment to Oversight: Strengthening AI Risk Management and Patient Safety in Health Care
Overview of Censinet's AI Governance, Risk & Compliance Webinar Series
Censinet’s webinar series turns the AI governance gap into something teams can actually use: a practical operating model for health systems. It gives healthcare organizations a clear framework for assessing AI risk, tightening governance, and making safer deployment decisions. That matters right now because AI is moving into hospital workflows faster than governance is catching up.
Core Themes: Governance Standards, Oversight, and Lifecycle Risk Management
The series looks at AI risk across the full lifecycle. That includes governance standards, policy design, risk classification, procurement review, implementation controls, continuous monitoring, and decommissioning. It also gives a preview of healthcare-specific governance guidance, including ANSI/HSI 2800:2025, the first American national standard for AI governance in healthcare operations.
This lifecycle view is a big deal. Risk doesn’t stop once a tool goes live. Procurement, contracting, monitoring, and decommissioning all stay on the governance checklist after launch.
Who Inside a Health System Should Use This Series
This series is built for security, IT, compliance, clinical, legal, and executive teams because AI governance in healthcare is shared work. No single group can handle it alone. The table below shows the main stakeholder groups and how each can use the series.
| Role | Primary Use of the Series |
|---|---|
| CISOs / Security Teams | Defending against AI-specific attack vectors, managing agentic AI vulnerabilities, and building AI-focused vulnerability management programs |
| CIOs / IT Leadership | Aligning AI deployment with enterprise risk frameworks and maintaining a formal AI inventory |
| Chief AI Officers | Establishing accountability structures and oversight models across the full AI lifecycle |
| Compliance & Privacy Leaders | Aligning internal policies with ANSI/HSI 2800:2025 |
| Procurement & Vendor Risk Teams | Applying the HSCC Third-Party AI Risk and Supply Chain Transparency Guide to vendor evaluations |
| Clinical Engineering & Clinical Leadership | Supporting human-AI partnership in clinical decision support and workflow integration |
| Legal Teams | Reviewing policy and contracting considerations tied to AI vendor relationships |
| Board Members & Executives | Reviewing AI risk reports, understanding accountability requirements, and preparing for disclosure attestations |
Those shared responsibilities set up the board oversight and vendor-risk guidance that comes next.
What the Series Teaches About AI Governance and Board Oversight
Building on the shared roles above, the series treats AI oversight as a committee-level job, not a side task for one team. It presents AI oversight as a lifecycle process that starts at intake and runs all the way to retirement.
How to Build a Cross-Functional AI Governance Model for Healthcare
Use a formal cross-functional AI governance committee with representation from cybersecurity, compliance, legal, privacy, clinical, procurement, and executive leadership. That setup helps keep AI decisions consistent and connected to enterprise risk management.
The series shows how governance lines up with the full AI lifecycle:
| Lifecycle Phase | Governance Focus Area | Key Stakeholders |
|---|---|---|
| Intake/Procurement | Vendor due diligence and supply-chain review | Procurement, Legal, CISO |
| Validation/Deployment | Workflow fit and safety testing | Clinical Leaders, Informatics |
| Monitoring | Continuous monitoring and threat detection | Security Operations, IT |
| Retirement | Decommissioning and retention planning | Risk Management, Legal |
That lifecycle view also shapes what leaders should expect to see in board reporting.
What Boards Need to See in AI Risk Reports
Board reports should cover patient safety, cybersecurity incidents, third-party exposure, regulatory status, and open governance gaps. They should also make clear which risks come from vendors, integrations, or downstream dependencies.
sbb-itb-535baee
How the Series Addresses Third-Party AI Risk, Vendor Review, and Supply Chain Exposure
7-Phase AI Third-Party Risk Lifecycle for Healthcare
Once AI governance is set, vendor review becomes the next place where things can go right - or go off the rails. This webinar series pushes vendor management beyond the usual checklist and into AI-focused due diligence, contract terms, and supply-chain visibility.
AI Vendor Due Diligence Across Procurement, Contracting, and Monitoring
The series lays out a 7-phase AI third-party risk lifecycle: use case justification, assessment, contracting, implementation, monitoring, incident response, and end-of-life planning.[1][3]
It spends the most time on contracting controls. And that makes sense. If the contract is vague, the rest of the review can fall apart fast. The series recommends AI-specific contract and BAA terms that address data residency, PHI retraining, breach timelines, audit rights, and required notice of model updates and related risk impact.[1][4][5][6]
Fourth-party exposure is often the hardest part of AI supply-chain risk to see clearly. Many AI vendors rely on foundation model providers, cloud services, and open-source libraries, and those dependencies can affect both security and compliance.[2] The webinars recommend mapping those dependencies directly and requiring vendors to disclose them.
Comparison Table: Standard Vendor Checks vs. AI-Specific Risk Reviews
The comparison below shows where AI tools need deeper review than standard vendor checks.
| Assessment Domain | Standard Third-Party Risk | AI-Specific Risk Review |
|---|---|---|
| Data Lineage | Data storage and encryption at rest/in transit | Training data sources, data provenance, and protection against data poisoning |
| Model Behavior | Software versioning and patch management | Monitoring for model drift, explainability of outputs, and change management for retrained models |
| Dependencies | Primary subcontractors and data center locations | Fourth-party dependencies, foundation model providers, and open-source library transparency |
| Threat Surface | Vulnerability scanning and penetration testing | Defense against prompt injection, agent hijacking, and AI-specific attack vectors |
| Autonomy | Role-based access control (RBAC) for human users | Permissions for autonomous agents, kill-switch capabilities, and human-in-the-loop requirements |
| Contracts/BAAs | Standard HIPAA BAA language | AI-specific provisions on PHI retraining, data destruction, breach notification, and audit rights |
These gaps matter because third-party AI risk can turn into a patient safety and cybersecurity problem fast. Censinet RiskOps™ and Censinet AI™ can help teams collect evidence, map fourth-party exposure, and summarize risk results.
Security, Patient Safety, and Next Steps from the Webinar Series
AI Threats That Matter Most in Healthcare Operations
Once governance and vendor review are in place, the next job is simpler to say than to do: understand the AI failure modes those controls need to stop. These are the risks governance, procurement, and security teams need to deal with both before launch and after deployment.
Prompt injection and agent hijacking can lead to unauthorized workflow execution and PHI exposure. If malicious inputs manipulate autonomous agents, those agents may carry out clinical workflows without approval or expose PHI through elevated permissions. The main safeguards are defined action boundaries, segmentation, human-in-the-loop checkpoints, and continuous monitoring of agent inputs and outputs. Model theft and exfiltration sit on a similar attack surface. If attackers go after proprietary clinical models, access controls, exfiltration detection, and incident response planning can cut that risk.
Data poisoning, hallucinations, and drift can lead to biased or harmful recommendations and weaken clinical decision support. The main controls here are drift testing, evidence validation, output quality monitoring, and human-in-the-loop clinical review. Automation bias adds another layer of risk. If clinicians lean too heavily on flawed outputs, errors can slip through, which is why policy enforcement and workforce training matter.
Autonomous agent misuse can trigger unintended transactions or record changes. Rollback capabilities, continuous audit trails, and documented action boundaries help stop that from turning into a bigger mess. Supply chain exposure and shadow AI create hidden compliance and operational risk when unapproved tools operate outside the governance inventory.
Comparison Table: AI Threat Categories, Healthcare Impact, and Recommended Controls
The table below pulls the highest-risk scenarios into one place and pairs them with the controls most likely to reduce them.
| AI Threat Category | Healthcare Operational Impact | Recommended Governance/Security Controls |
|---|---|---|
| Prompt Injection / Agent Hijacking | Unauthorized execution of clinical workflows; manipulation of autonomous agents; PHI exfiltration through elevated permissions | Defined action boundaries; human-in-the-loop checkpoints; segmentation; continuous monitoring of agent inputs and outputs |
| Data Poisoning / Hallucinations / Model Drift | Biased or harmful treatment recommendations; degraded clinical decision support | Drift testing; evidence validation; output quality monitoring; automated risk telemetry; human-in-the-loop clinical review |
| Automation Bias | Clinician over-reliance leading to diagnostic errors or missed errors | Policy enforcement; workforce training; human-AI partnership frameworks |
| Model Theft / Exfiltration | Loss of proprietary clinical models; intellectual property exposure | Access controls; exfiltration detection; incident response planning |
| Autonomous Agent Misuse | Unintended transactions or record modifications without human review | Rollback capabilities; continuous audit trails; documented action boundaries |
| Supply Chain / Shadow AI | Unapproved tools outside governance; hidden operational and compliance risk | Automated inventory tracking; centralized dashboards; approved-use enforcement |
Conclusion: How Healthcare Leaders Can Apply the Series to AI Decisions
Put together, these controls turn webinar guidance into day-to-day operating choices. The series gives healthcare organizations a framework they can use, not just admire from a distance. The core point is straightforward: AI risk needs to sit inside enterprise risk management, third-party oversight programs, and AI governance workflows at the same time. That only works when cybersecurity, compliance, and patient safety stay aligned.
Censinet RiskOps™ and Censinet AI™ support this approach by centralizing AI-related policies, risks, and tasks, routing findings to the right governance stakeholders, and keeping human oversight in automated workflows. For healthcare leaders ready to move from insight to action, the next step is mapping AI use cases to threats, owners, and controls.
FAQs
How do we start AI governance before deployment?
Start with an operating model that says one simple thing: no AI tool goes live until it has been reviewed and approved. That model should sit on top of a clear governance charter that spells out who decides what across clinical, security, privacy, compliance, legal, and executive teams.
Then turn that into day-to-day work with a few concrete moves:
- a multidisciplinary governance committee
- a written policy that defines permitted and prohibited uses
- a centralized AI risk register
- risk-tiered approval workflows tied to procurement, IT intake, and change management
This matters because AI doesn't fit neatly into one department. A clinical team may care about patient impact. Security may focus on data exposure. Legal may look at contract terms and liability. Leadership may focus on business risk and oversight. If no one owns the handoff points, tools can slip through the cracks.
A good governance setup makes those handoffs clear. It gives teams a shared path for review instead of a last-minute scramble after a tool is already in use. In plain terms, it moves AI adoption from ad hoc to controlled.
What should boards review about AI risk?
Boards should treat AI governance as an ongoing patient safety duty, not just an IT task. That means asking for one clear inventory of every AI tool in use, including tools built into EHRs and vendor platforms.
They should also review quarterly reports that cover high-risk use cases, validation status, incidents, open gaps, and issue owners. Those reports should also show proof of human-in-the-loop workflows, vendor transparency, and resilience plans for AI outages or clinical failures.
How is AI vendor review different from standard software review?
AI vendor review isn’t the same as a standard software review. With regular software, a static questionnaire may cover most of the ground. AI is different. Its supply chain can shift over time, parts of it may be hard to see, and the models themselves can change in ways a one-time review won’t catch.
That’s why AI vendor review needs ongoing governance, not a one-and-done check. Teams have to watch for risks like model drift, data poisoning, and prompt injection. They also need a closer look at how PHI is used, whether data is shared with other parties, how retraining happens, and what all of this could mean for clinical care and patient safety.
